| Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double‐blind, placebo … EHS Choy, DA Isenberg, T Garrood, S Farrow, Y Ioannou, H Bird, ... Arthritis & Rheumatism 46 (12), 3143-3150, 2002 | 647 | 2002 |
| A review of gastrointestinal manifestations of systemic lupus erythematosus SM Sultan, Y Ioannou, DA Isenberg Rheumatology 38 (10), 917-932, 1999 | 390 | 1999 |
| Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy Y Ioannou, DA Isenberg Arthritis & Rheumatism: Official Journal of the American College of …, 2000 | 317 | 2000 |
| Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality SM Sultan, Y Ioannou, K Moss, DA Isenberg Rheumatology 41 (1), 22-26, 2002 | 313 | 2002 |
| How we diagnose the antiphospholipid syndrome B Giannakopoulos, F Passam, Y Ioannou, SA Krilis Blood, The Journal of the American Society of Hematology 113 (5), 985-994, 2009 | 249 | 2009 |
| Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades KE Moss, Y Ioannou, SM Sultan, I Haq, DA Isenberg Annals of the rheumatic diseases 61 (5), 409-413, 2002 | 239 | 2002 |
| Disease activity, severity, and damage in the UK juvenile‐onset systemic lupus erythematosus cohort L Watson, V Leone, C Pilkington, K Tullus, S Rangaraj, JE McDonagh, ... Arthritis & Rheumatism 64 (7), 2356-2365, 2012 | 235 | 2012 |
| Differences in disease phenotype and severity in SLE across age groups N Ambrose, TA Morgan, J Galloway, Y Ionnoau, MW Beresford, ... Lupus 25 (14), 1542-1550, 2016 | 227 | 2016 |
| Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human β2‐glycoprotein I: Mutation studies including residues R39 to R43 Y Ioannou, C Pericleous, I Giles, DS Latchman, DA Isenberg, A Rahman Arthritis & Rheumatism 56 (1), 280-290, 2007 | 181 | 2007 |
| Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate D Pyne, Y Ioannou, R Mootoo, A Bhanji Clinical rheumatology 23, 116-120, 2004 | 148 | 2004 |
| Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long‐term review SM Sultan, Y Ioannou, DA Isenberg Rheumatology 39 (10), 1147-1152, 2000 | 146 | 2000 |
| In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept Y Ioannou, ZR Penabad, C Pericleous, I Giles, E Papalardo, G Vargas, ... Journal of thrombosis and haemostasis 7 (5), 833-842, 2009 | 141 | 2009 |
| Naturally occurring free thiols within β2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress–induced cell injury Y Ioannou, JY Zhang, FH Passam, S Rahgozar, JC Qi, B Giannakopoulos, ... Blood, The Journal of the American Society of Hematology 116 (11), 1961-1970, 2010 | 132 | 2010 |
| Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration K Webb, H Peckham, A Radziszewska, M Menon, P Oliveri, F Simpson, ... Frontiers in immunology 9, 3167, 2019 | 121 | 2019 |
| Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2‐glycoprotein I Y Ioannou, JY Zhang, M Qi, L Gao, JC Qi, DM Yu, H Lau, AD Sturgess, ... Arthritis & Rheumatism 63 (9), 2774-2782, 2011 | 121 | 2011 |
| Integrative analysis reveals a molecular stratification of systemic autoimmune diseases G Barturen, S Babaei, F Català‐Moll, M Martínez‐Bueno, Z Makowska, ... Arthritis & rheumatology 73 (6), 1073-1085, 2021 | 103 | 2021 |
| Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Y Ioannou, DA Isenberg Postgraduate medical journal 78 (924), 599-606, 2002 | 90 | 2002 |
| Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome C Pericleous, I Ferreira, O Borghi, F Pregnolato, T McDonnell, ... PLoS one 11 (6), e0156407, 2016 | 83 | 2016 |
| Beta 2 glycoprotein I is a substrate of thiol oxidoreductases FH Passam, S Rahgozar, M Qi, MJ Raftery, JWH Wong, K Tanaka, ... Blood, The Journal of the American Society of Hematology 116 (11), 1995-1997, 2010 | 83 | 2010 |
| Developing and evaluating JIApp: acceptability and usability of a smartphone app system to improve self-management in young people with juvenile idiopathic arthritis RA Cai, D Beste, H Chaplin, S Varakliotis, L Suffield, F Josephs, D Sen, ... JMIR mHealth and uHealth 5 (8), e7229, 2017 | 78 | 2017 |
Lucy WedderburnUCL GOS Institute of Child healthVerified email at ucl.ac.uk
